(Sharecast News) - Avacta Group said on Tuesday that it had strengthened its position as a pure-play oncology biopharmaceutical company during 2025, with progress across its 'preCISION' tumour-activated drug delivery platform and cash runway extended into the first quarter of 2027.
The AIM-traded clinical-stage company said cash and short-term deposits stood...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE